How to Value a Mammography Center in 2026

Mammography centers are a niche within imaging M&A that most generalist advisors get wrong. The reimbursement is thinner than MRI or CT, the regulatory overhead is meaningfully higher, and the patient experience matters in ways that commodity imaging simply doesn't. But the centers that are well-run, properly accredited, and positioned as a women's health destination trade at surprisingly strong multiples — typically 5-8x EBITDA, and occasionally north of that when a strategic like Solis Mammography or a regional hospital system is building out market share.

I've walked sellers through this market more than a few times, and the consistent theme is that breast imaging is valued on volume, mix, and brand — in that order. Here's how it actually works in 2026.

The Multiples: Where Mammography Centers Trade

Independent mammography and breast imaging centers trade in a 5-8x EBITDA range, with most outpatient deals closing between 5.5x and 7x. The higher end of the range requires three things at once: strong screening volume (10,000+ annual studies), 3D tomosynthesis capability, and a full breast imaging service line (screening, diagnostic, ultrasound, biopsy) — not just a screening mill.

A well-run women's imaging center doing $3.5M in revenue and $800K EBITDA typically transacts for $4.5-5.8M. The real outliers — multi-site women's imaging platforms — can push to 8-10x because they become platform assets for consolidators like Solis Mammography, RadNet's women's imaging division, or regional hospital systems trying to build a breast health service line.

One thing to be honest about: standalone single-site mammography centers with under $400K in EBITDA rarely attract strategic interest. The floor buyers are usually regional imaging operators picking up tuck-ins, and multiples at that end of the market are closer to 4.5-5.5x.

MQSA Accreditation: The Non-Negotiable Foundation

Every mammography center in the U.S. must be certified under the FDA's Mammography Quality Standards Act (MQSA), accredited by the ACR (or a state equivalent in a handful of states), and inspected annually. This isn't optional, and buyers start every diligence conversation by asking for your current MQSA certificate and the most recent inspection report.

What sellers underestimate is how much a clean MQSA record is worth in a transaction. A center with no deficiencies over the last three inspection cycles, up-to-date medical physicist annual surveys, and documented interpreting physician continuing experience requirements (960 studies over 24 months per radiologist) signals operational discipline. Buyers will push multiples by 0.2-0.5x for that.

Conversely, any open MQSA deficiency — a physicist survey overdue, a radiologist short on continuing experience, a phantom score out of tolerance — will either stall your deal or get repriced in diligence. I've seen a $5M transaction repriced by $600K because a lead interpreting physician was 120 studies short of the MQSA continuing experience requirement and buyers flagged it as a going- concern risk.

Volume and the Screening-to-Diagnostic Mix

Mammography reimburses poorly per study. Medicare pays roughly $135 for a screening mammogram (CPT 77067) and about $165-185 for a diagnostic mammogram. Commercial payers run 130-160% of Medicare. Tomosynthesis (3D) adds a modest technical add-on — typically $50-60 per study on Medicare. The numbers are small enough that volume has to be the engine of the business.

My volume benchmarks:

• Under 5,000 screenings/year: Subscale. Hard to cover fixed overhead profitably. Multiples at 4.5-5.0x if you can find a buyer.
• 5,000-9,000 screenings/year: Workable. 5.5-6.5x for a well-run single site.
• 10,000-15,000 screenings/year: Attractive. 6.5-7.5x, especially with a diagnostic/biopsy book on top.
• 15,000+ screenings/year: Strategic target. 7.5-8.5x, and platform multiples if you have multiple sites.

The screening-to-diagnostic mix matters enormously for margin. Screening is high volume but thin margin — it's the loss leader that feeds the rest of the business. Diagnostic mammography, breast ultrasound, and stereotactic/ultrasound-guided biopsy are where margin actually comes from. A center running 70% screening / 30% diagnostic + intervention will have meaningfully better EBITDA margins than one running 90% screening.

Equipment: 3D Tomosynthesis Is Now Table Stakes

Ten years ago, 3D tomosynthesis (DBT) was a differentiator. In 2026, it's the baseline. A center still running 2D-only mammography is signaling to buyers that the equipment is old, the capital budget has been neglected, and the owner is avoiding the inevitable upgrade cost. Expect a 0.5-1.0x multiple discount if you're not at least partially on DBT.

What buyers actually look for:

• DBT-capable units (Hologic Selenia Dimensions, GE Senographe Pristina, Siemens Mammomat Revelation) under 8 years old.
• Dedicated breast ultrasound with elastography capability.
• Stereotactic or upright biopsy capability on-site.
• Breast MRI if you're positioning as a comprehensive women's imaging destination (via partnership or co-located).

The Women's Health Positioning Premium

Mammography is the only imaging modality where the patient experience is a material valuation driver. Unlike MRI or CT, where patients mostly go where they're sent, screening mammography is a repeat annual decision where patient preference actually moves volume. Centers that have invested in a premium women's health experience — private gowns, warm design, female technologists, same-day results programs — build a local brand that generates real volume loyalty.

Buyers pay up for this. Solis Mammography has built its entire brand on the premium women's health model, and when they acquire, they're looking for centers that already have a compatible patient experience. A center that feels like a commodity imaging facility will get valued as one.

What Destroys Mammography Center Value

Aging equipment with no upgrade path. 2D-only units past year 10, no DBT, no ultrasound. Buyers price this at replacement cost deduction — typically $300-500K off enterprise value per unit.

A single interpreting radiologist. If all your reads come from one radiologist, and that radiologist isn't contractually committed to stay post-close, MQSA continuing experience requirements become a going-concern risk. Diversify your reader panel before going to market.

Declining screening volume. Two years of declining screening counts is a red flag that suggests a referral base problem or a patient experience issue. Fix this before you sell.

Messy billing. Mammography billing involves technical component, professional component, DBT add-on codes, and CAD (computer-aided detection) modifiers. Centers that bill sloppily leak 5-10% of revenue, and that shows up in quality of earnings diligence.

How to Maximize Your Exit

Get to 3D if you haven't already. A DBT upgrade costs $250-400K used or $450-650K new, and it pays for itself in the multiple alone.

Build the diagnostic and biopsy service line. Screening alone is thin. Adding ultrasound, stereotactic biopsy, and diagnostic workup changes the margin profile meaningfully.

Document your patient experience. If you've built a premium women's health brand, put the numbers behind it — NPS scores, repeat screening rates, patient reviews. Buyers pay for proof, not claims.

Clean up your MQSA file. Make sure every physicist survey, radiologist continuing experience log, and inspection report is current before the first buyer walks in the door.

Run the numbers. An instant valuation will give you a defensible range to anchor negotiations.

The Bottom Line

Mammography centers are a specialized asset class with a specialized buyer pool. The 5-8x EBITDA band is real, but where you land within it depends on screening volume, equipment modernization, service line breadth, MQSA compliance, and brand positioning. Owners who treat their center as a women's health destination — not a commodity imaging facility — consistently exit at the high end of the range. Owners who treat it as a regulated mammography box get priced accordingly.